Bristol Myers Wins FDA Approval for Zenbexus, Debuting New Myeloma Drug Class
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs for the blood cancer.
The clearance of Zenbexus is the first for a group of protein-degrading CELMoD molecules, showcasing Bristol Myers' continued innovation in oncology treatments.
Bristol Myers
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene“The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.”
stat news — STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class